Catabasis Pharmaceuticals (CATB) Receives Coverage Optimism Score of 0.15

News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.770039841905 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Catabasis Pharmaceuticals (CATB) traded down $0.02 during midday trading on Tuesday, hitting $1.55. The stock had a trading volume of 163,000 shares, compared to its average volume of 287,860. The firm has a market capitalization of $35.79 and a PE ratio of -1.03. Catabasis Pharmaceuticals has a twelve month low of $1.08 and a twelve month high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million during the quarter. equities research analysts predict that Catabasis Pharmaceuticals will post -1.37 earnings per share for the current year.

CATB has been the subject of several research analyst reports. Citigroup upgraded Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, November 20th. Zacks Investment Research lowered Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 16th. Oppenheimer raised their price target on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday, October 5th. CIBC restated an “outperform” rating and set a $7.00 price target (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cowen restated a “market perform” rating and set a $2.00 price target on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $4.82.

TRADEMARK VIOLATION NOTICE: “Catabasis Pharmaceuticals (CATB) Receives Coverage Optimism Score of 0.15” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/09/catabasis-pharmaceuticals-catb-receives-coverage-optimism-score-of-0-15.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

What are top analysts saying about Catabasis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catabasis Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit